Walter and Eliza Hall Institute of Medical Research
VC Fund
Parkville, Australia
Walter and Eliza Hall Institute of Medical Research is a VC fund in Parkville focused on Medical and Biopharma. Walter and Eliza Hall Institute of Medical Research offers discoveries for cancer, infection, aging, medicines and advanced technologies.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Walter and Eliza Hall Institute of Medical Research invests in
Stages Walter and Eliza Hall Institute of Medical Research invests in
Countries Walter and Eliza Hall Institute of Medical Research invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Komander
|
|||
Ueli Nachbur
|
|||
Investment Focus
Industry
- Medical 1 (50%)
- Biopharma 1 (50%)
- Life Science 1 (50%)
- Biotechnology 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Komander
Head, Ubiquitin Signalling Division
|
Head, Ubiquitin Signalling Division | Total investments: 1 | Find email | |
|
Ueli Nachbur
Scientist Entrepreneur
|
Scientist Entrepreneur | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Entact Bio
|
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M / Series A / Dec 06, 2022 | |
|
Entact Bio
|
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M / Series A / Dec 06, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Walter and Eliza Hall Institute of Medical Research invest in?
Walter and Eliza Hall Institute of Medical Research invests primarily in Medical, Biopharma and Life Science startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Walter and Eliza Hall Institute of Medical Research?
Public channels for Walter and Eliza Hall Institute of Medical Research include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Walter and Eliza Hall Institute of Medical Research?
The team at Walter and Eliza Hall Institute of Medical Research includes David Komander (Head, Ubiquitin Signalling Division) and Ueli Nachbur (Scientist Entrepreneur). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
